v3.26.1
Revenue
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recognizes revenue in accordance with ASC 606 on the basis of its satisfaction of outstanding performance obligations. The Company typically fulfills its performance obligations over time, either over the course of a single treatment (fee-for-service or "FFS"), a month (capitation), or a number of months (clinical research). The Company also has revenue that is satisfied at a point in time (specialty pharmacy).
Disaggregation of Revenue
The Company categorizes revenue based on various factors such as the nature of contracts, payors, order to billing arrangements, and cash flows received by the Company, as follows:
(in thousands)Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Patient services
Capitated revenue$27,974 $18,843 $54,905 $36,338 
FFS revenue30,85337,04863,00972,621
Subtotal58,827 55,891 117,914 108,959 
Specialty pharmacy revenue98,608 62,573 186,149 111,866 
Clinical research trials and other revenue3,847 1,338 4,660 3,383 
Total$161,282 $119,802 $308,723 $224,208 
Refer to Note 19 for Segment Reporting for disaggregation of revenue by reporting segment.
Contract Asset and Liabilities
Under ASC 606, contract assets represent rights to payment for performance contingent on something other than the passage of time and accounts receivable are rights to payment for performance without contingencies. The Company does not have any contract assets as of June 30, 2026, January 1, 2025, and December 31, 2025. Refer to Note 4 for accounts receivable as of June 30, 2026 and December 31, 2025.
Contract liabilities represent cash that has been received for contracts, but for which performance is still unsatisfied. As of January 1, 2025, December 31, 2025, and June 30, 2026, the contract liabilities amounted to $0. During the three month periods ended June 30, 2026 and 2025, the Company recognized no revenue related to deferred capitation revenue received (contract liability) as of the beginning of each respective period.
Remaining Unsatisfied Performance Obligations
The accounting terms for the Company’s patient services and specialty pharmacy contracts do not extend past a year in duration. Additionally, the Company applies the ‘as invoiced’ practical expedient to its clinical research contracts.